Hereditary hemorrhagic telangiectasia (HHT) is an autosomal-dominant disorder associated with multiple arteriovenous malformations. This causes HHT patients to suffer repeated bleeding episodes, which may require red blood cell (RBC) transfusions. Since hemorrhage in HHT leads to RBC leakage into submucosal tissue (which could facilitate increased RBC antigen presentation in local draining lymph nodes), we hypothesized that HHT patients may be prone to higher RBC alloimmunization rates than other transfused patients whose RBCs remain in the intravascular space and are cleared by the spleen and liver. As such, we undertook a retrospective study of the alloimmunization rates and properties of HHT patients at our facility, a referral center for this disorder. For HHT patients seen at the study site, the following was collected: gender, age, number of RBC transfusions, and number/specificities of non-ABO alloantibodies identified. A group of randomly selected, chronically transfused patients without HHT was used as controls (n = 207); each of these control subjects underwent at least one follow-up antibody test after the first RBC transfusion. Statistical comparisons were done using the Student t-test or the χ 2 test with Yates correction for continuity, with P values < .05 considered significant. Overall, we identified 122 patients with HHT at our site, of which 85 underwent antibody screens and for whom additional data were collected. Among these HHT patients, 13 were alloimmunized, yielding an alloimmunization rate of 15.3% (13/85). Alloimmunized HHT subjects formed 31 antibodies, developing 2.4 antibodies per patient (13/31). Anti-E, -K, and -c were the three most common alloantibodies identified. HHT patients received a mean 4.3 ± 6.6 RBC units at our facility. Notably, female HHT patients had lower alloimmunization rates than male patients (female rate 10.0% vs male rate 22.9%) despite more mean RBC transfusions in women (female 5.5 units vs male 2.5 units; P = .0149). We found a significantly higher alloimmunization rate among HHT patients than controls (15.3% vs 2.4%; P < .001) even though control patients received significantly more RBC transfusions (8.5 vs 4.3 units; P < .0001). There was also a trend for HHT patients to make more antibodies per alloimmunized patient than controls (2.4 vs 1.6), although this was not statistically significant. In conclusion, this study is the first to show that HHT patients are alloimmunized at high rates, approaching 6-7x that of controls. Prophylactic antigen matching may be reasonable for this patient population, with consideration of matching for the immunogenic C/c, E/e, and K antigens. Additional studies are warranted to better examine the "responder" phenotype among HHT patients.
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal-dominant disorder associated with multiple arteriovenous malformations. This causes HHT patients to suffer repeated bleeding episodes, which may require red blood cell (RBC) transfusions. Since hemorrhage in HHT leads to RBC leakage into submucosal tissue (which could facilitate increased RBC antigen presentation in local draining lymph nodes), we hypothesized that HHT patients may be prone to higher RBC alloimmunization rates than other transfused patients whose RBCs remain in the intravascular space and are cleared by the spleen and liver. As such, we undertook a retrospective study of the alloimmunization rates and properties of HHT patients at our facility, a referral center for this disorder. For HHT patients seen at the study site, the following was collected: gender, age, number of RBC transfusions, and number/specificities of non-ABO alloantibodies identified. A group of randomly selected, chronically transfused patients without HHT was used as controls (n = 207); each of these control subjects underwent at least one follow-up antibody test after the first RBC transfusion. Statistical comparisons were done using the Student t-test or the χ 2 test with Yates correction for continuity, with P values < .05 considered significant. Overall, we identified 122 patients with HHT at our site, of which 85 underwent antibody screens and for whom additional data were collected. Among these HHT patients, 13 were alloimmunized, yielding an alloimmunization rate of 15.3% (13/85). Alloimmunized HHT subjects formed 31 antibodies, developing 2.4 antibodies per patient (13/31). Anti-E, -K, and -c were the three most common alloantibodies identified. HHT patients received a mean 4.3 ± 6.6 RBC units at our facility. Notably, female HHT patients had lower alloimmunization rates than male patients (female rate 10.0% vs male rate 22.9%) despite more mean RBC transfusions in women (female 5.5 units vs male 2.5 units; P = .0149). We found a significantly higher alloimmunization rate among HHT patients than controls (15.3% vs 2.4%; P < .001) even though control patients received significantly more RBC transfusions (8.5 vs 4.3 units; P < .0001). There was also a trend for HHT patients to make more antibodies per alloimmunized patient than controls (2.4 vs 1.6), although this was not statistically significant. In conclusion, this study is the first to show that HHT patients are alloimmunized at high rates, approaching 6-7x that of controls. Prophylactic antigen matching may be reasonable for this patient population, with consideration of matching for the immunogenic C/c, E/e, and K antigens. Additional studies are warranted to better examine the "responder" phenotype among HHT patients. Background: As a key regulator of angiogenesis, vascular endothelial growth factor (VEGF) plays an important role in physiology of normal ovaries and pathogenesis of ovarian cancer, such as tumorigenesis and metastasis. The objective of this study was to assess the association of genetic variants in the VEGF pathway with ovarian cancer risk, therapeutic response, and survival. Patients and Methods: A cohort of 339 ovarian cancer patients matched with 349 healthy controls by age, gender, and ethnicity were tested for single nucleotide polymorphisms (SNPs) in VEGF and VEGF receptor (VEGFR) genes using the Illumina iSelect platform. The statistical analyses were performed using Intercooled STATA software. P value ≤ .05 was considered significant. The overall risk of ovarian cancer and likelihood of poor treatment response were estimated as odds ratios (ORs) with 95% confidence intervals (CIs) for each SNP using unconditional multivariate logistic regression. The overall risk of death was estimated as hazard ratios (HRs) and 95% CIs for each SNP using the Cox proportional hazards model. Results: Sixteen SNPs from five genes in the VEGF-VEGFR axis were identified as significantly associated with an increased risk of ovarian cancer, among which VEGFR-3 rs6877011 showed the highest risk of ovarian cancer (OR 1.66, 95% CI 1.09-2.53), while VEGFR-1 rs11149523 showed the lowest risk (OR 0.51, 95% CI 0.32-0.83). Ten SNPs from four genes were identified as significantly associated with platinum-based chemotherapeutic response, among which VEGFR-2 rs1531289 was associated with a favorable treatment response (OR 0.64, 95% CI 0.42-0.98), and all the other variants showed a significant association with a poor chemotherapeutic response. In particular, VEGFR-1 rs8000288 showed the highest risk of poor chemotherapeutic response (OR 4.25, 95% CI 1.10-16.43). Twelve SNPs from four genes were identified as significantly associated with the overall survival of ovarian cancer patients, among which fms like tyrosine kinase 3 (Flt3) rs3003955 was the most significant variant associated with improved prognosis (HR 0.59, 95% CI 0.41-0.84), while VEGFR-1 rs17626553 was the most significant one associated with poor prognosis (HR 4.07, 95% CI 1.86-8.92). Conclusions: Multiple genetic variants in the VEGF pathway significantly associated with ovarian cancer risk, therapeutic response, and survival are identified in our study. These findings may provide a potential molecular approach for ovarian cancer risk assessment, patient management and clinical outcome prediction. Vanderbilt University, Nashville, TN B-cell lymphomas and leukemias have an annual incidence of ~95,000 cases. They exhibit alterations in genes in "targetable" signaling pathways, enabling a precision medicine approach for therapeutic decisions. However, molecular genetic testing is not yet standard of care for non-Hodgkin lymphoma (NHL). Therefore, we have used whole transcriptome profiling by RNA-seq to simultaneously identify mutations and expression changes in B-cell cancers. We have profiled ~70 primary B-cell cancers and ~50 primary normal B-lymphocyte subsets (naïve, germinal center, memory, and in vitro activated). We first compared gene expression in tumor types to normal B-cell subsets. Our approach segregated major tumor subtypes (follicular [FL] and germinal center B [GCB] or activated [ABC] diffuse large B-cell lymphomas [DLBCLs] , chronic lymphocytic leukemia [CLL] ) and revealed two novel subtypes of FL. We also identified tumors with overexpression of genes that are associated with poor prognosis (BCL2, MYC). Variants were identified by at least two variant callers and met stringent quality filters; common SNPs (>1% frequency) were excluded. We identified mutations in chromatin modifier, transcription factor, and B-cell receptor signaling proteins. To evaluate the functional impact of these mutations, we designed a method to calculate the expressed mutant allele ratio (EMAR). In general, these ratios corresponded to the proportion of tumor cells. However, the EMAR of some genes was substantially higher than the proportion of tumor cells, which we termed skewed EMAR. This could be caused by a high mutational burden in non-tumor cells. Indeed, the genomes of normal and malignant B cells exhibit evidence of activation-induced cytidine deaminase (AID) activity, which mediates somatic hypermutation. However, AID activity is not limited to Ig genes; mutations in several lymphoma proto-oncogenes are induced by AID. In fact, some of the genes with skewed EMAR are known AID off-targets (BCL2, BCL6, PAX5). Notably, several other genes with a skewed EMAR have not previously been associated with AID activity. Finally, we have previously shown that sequence variants in non-coding gene regulatory regions promote tumorigenesis by deregulating expression. Therefore, we calculated the burden of sequence variation to one megabase resolution across the transcriptome. Strikingly, we identified several novel regions with significantly enriched mutation burden, the majority of which overlapped NHL enhancers. One of these is flanked by two immunoglobulin receptor genes, FCMR and PIGR, which are associated with CLL (FCMR) or autoimmune disease (PIGR). The mechanisms by which these genes are deregulated and promote disease have not been defined, but the non-coding regulatory mutations we identified may play a role. In summary, this study demonstrates the power of RNA-seq to discover novel mechanisms of lymphomagenesis and to simultaneously identify mutations and expression changes that stratify risk and suggest effective therapies. It has been established that specific groups of patients immunologically respond more readily than others to red blood cell antigens; such patients have been termed "responders" and "nonresponders". While it is clear that red blood cell (RBC) antigenic differences between donors and recipients are required for humoral immune responsiveness, other variables are also involved. Previous investigations have demonstrated that there is significant primary sequence identity between common RBC antigens and established microbes, and that immunogenic cross-reactivity is possible between such antigens in experimental models. Based on this previous work, we hypothesized that responder populations may be immunologically primed to form RBC alloantibodies via environmental exposure to microbial antigens that are cross-reactive with common RBC antigens, and that such a correlation may be intrinsically linked to observed blood group antigen immunogenicities. To examine this hypothesis, we performed peptide homology searches of the most immunogenic RBC antigens, based on previously published antigenicity findings. Thirteen amino
A Precision Medicine Approach Using Whole Transcriptome Profiling by RNA-seq for B Cell Cancers

